Online inquiry

IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14740MR)

This product GTTS-WQ14740MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in B cell acute lymphoblastic leukemia (B cell ALL), Refractory B-lineage non-Hodgkin lymphoma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ14740MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13026MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ4538MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-936558
GTTS-WQ4740MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BPS-804
GTTS-WQ11530MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ11664MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ181MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ11477MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ5651MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDX-011
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW